Project Pipeline
-
ARE 001 Managing meal-time glucose spikes remains an elusive goal for many insulin-treated patients with diabetes. ARE 001 aims to put an end to "swings and roundabouts" and the catch-up cycle of high blood glucose peaks and hypoglycaemic valleys.
-
ARE 002 Patients with morbid obesity face severe restrictions in activities of daily living. ARE 002 is foreseen to be an oral agent that leads to noteworthy sustained weight loss.
-
ARE 003 Type 2 Diabetes mellitus is the leading cause of blindness and end-stage renal disease in adults. It is characterized by a progressive loss in insulin secretion. ARE 003 promises to protect islet function making it the first truly disease-modifying oral anti-diabetic agent.
-
ARE 004 Aside from physical barriers and abstinence there are no means for contraception targeted at males available today. ARE 004 is intended as a safe reversible pharmacological contraceptive for men.
-
ARE 005 Benign Prostatic Hyperplasia (BPH) is a widespread condition of the elderly male. It is associated with lower urinary tract symptoms (LUTS) and secondary complications. ARE 005 has the potential to revolutionize the life-cycle management of the mature prostate.
-
ARE 006 Erectile dysfunction compromises quality of life and can lead to considerable psychological burden. Despite effective therapies there is considerable potential for improvement. ARE 006 is set to step up the management of erectile dysfunction.
-
ARE 007 Prostate cancer contributes to notable male morbidity and mortality. ARE 007 is directed towards anatomically targeted therapy of early prostate cancer.
-
ARE 008 An unfulfilled desire for offspring can be distressing and burdensome. ARE 008 explores new perspectives on male fertility.